Clinical Trial Update: A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors [Phase 1]

View source ↗

Summary

Phase I study of IAG933 in patients with malignant mesothelioma and other solid tumors is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• IAG933

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Mesothelioma | Phase 1 | Status: ACTIVE_NOT_RECRUITING